Literature DB >> 9723152

Plasma prolactin response to D-fenfluramine is blunted in bulimic patients with frequent binge episodes.

P Monteleone1, F Brambilla, F Bortolotti, C Ferraro, M Maj.   

Abstract

BACKGROUND: Abnormalities of brain serotonin (5-HT) transmission have been implicated in the pathophysiology of bulimia nervosa (BN), but no conclusive data have yet been provided. The purpose of this study was to assess 5-HT transmission via the measurement of the prolactin (PRL) response to the specific 5-HT releasing agent D-fenfluramine (D-FEN) in both patients with BN and comparison subjects.
METHODS: According to a double-blind placebo-controlled design, plasma PRL response to D-FEN was measured in 14 drug-free bulimics and 14 matched healthy controls. In both patients and controls, eating-related psychopathology, depressive and obsessive-compulsive symptoms, and aggressiveness were measured by rating scales.
RESULTS: Baseline plasma levels of PRL and 17 beta-oestradiol were significantly reduced in bulimic patients, whereas basal plasma levels of cortisol did not significantly differ from healthy controls. PRL response to D-FEN was not different between patients and controls as groups, but it was significantly blunted in bulimics with high frequency bingeing (> or = 2 binge episodes per day; N = 7) as compared to both those with low frequency bingeing (< or = 1 binge episode per day; N = 7) and matched controls. A significant negative correlation emerged between the frequency of binge episodes and the hormone response to D-FEN. Moreover, although patients scored higher than healthy subjects on rating scales assessing depressive and obsessive-compulsive symptoms and aggressiveness, no significant correlation was found between these measures and the PRL response to D-FEN.
CONCLUSIONS: These results support the idea that serotonin transmission is impaired in bulimic patients with frequent binge episodes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9723152     DOI: 10.1017/s0033291798006904

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  6 in total

Review 1.  Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-V?

Authors:  Katharine A Phillips; Dan J Stein; Scott L Rauch; Eric Hollander; Brian A Fallon; Arthur Barsky; Naomi Fineberg; David Mataix-Cols; Ygor Arzeno Ferrão; Sanjaya Saxena; Sabine Wilhelm; Megan M Kelly; Lee Anna Clark; Anthony Pinto; O Joseph Bienvenu; Joanne Farrow; James Leckman
Journal:  Depress Anxiety       Date:  2010-06       Impact factor: 6.505

Review 2.  Revisiting the serotonin-aggression relation in humans: a meta-analysis.

Authors:  Aaron A Duke; Laurent Bègue; Rob Bell; Tory Eisenlohr-Moul
Journal:  Psychol Bull       Date:  2013-02-04       Impact factor: 17.737

Review 3.  Aetiopathogenesis and pathophysiology of bulimia nervosa: biological bases and implications for treatment.

Authors:  F Brambilla
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  Brain serotonin deficiency and fluoxetine lead to sex-specific effects on binge-like food consumption in mice.

Authors:  Melinda D Karth; Brittany J Baugher; Sophia A Pellechia; Shama N Huq; Allison K Warner; Michelle M Karth; Benjamin D Sachs
Journal:  Psychopharmacology (Berl)       Date:  2022-06-24       Impact factor: 4.415

5.  The possible influence of impulsivity and dietary restraint on associations between serotonin genes and binge eating.

Authors:  Sarah E Racine; Kristen M Culbert; Christine L Larson; Kelly L Klump
Journal:  J Psychiatr Res       Date:  2009-06-02       Impact factor: 4.791

6.  Impact of novel palmitoylated prolactin-releasing peptide analogs on metabolic changes in mice with diet-induced obesity.

Authors:  Veronika Pražienková; Martina Holubová; Helena Pelantová; Martina Bugáňová; Zdenko Pirník; Barbora Mikulášková; Andrea Popelová; Miroslava Blechová; Martin Haluzík; Blanka Železná; Marek Kuzma; Jaroslav Kuneš; Lenka Maletínská
Journal:  PLoS One       Date:  2017-08-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.